融资丨新动生物完成数千万元天使轮融资

Core Insights - New Dong Biological, a service platform dedicated to the evaluation of innovative pet drugs, has successfully completed an angel round financing of several tens of millions of yuan [4][6] - The financing was led by Wuhan Dongke Jucai Venture Capital Fund, with participation from several other investment funds, and will be used to expand animal testing facilities and accelerate the development of disease models and technology platforms [4][6] Company Overview - New Dong Biological has a strong entrepreneurial team with members from prestigious institutions such as Huazhong Agricultural University and Huazhong University of Science and Technology, as well as leading CRO companies [6][7] - The company has rapidly developed over nearly two years, delivering over 1,000 high-quality experimental animals and supporting three companies in completing cat trivalent vaccine re-examinations [7] Investment Insights - The representative of the investment firm highlighted the strong growth potential in the pet medical and pharmaceutical market, emphasizing New Dong Biological's unique competitive advantages and potential to become a "hidden champion" in the industry [6] - The investment fund, Wuhan Dongke Jucai, focuses on seed and early-stage technology enterprises, particularly in high-growth sectors such as life sciences and hard technology [8]